Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2000 Jun 19;191(12):2039–2052. doi: 10.1084/jem.191.12.2039

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2000 The Rockefeller University Press

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Effective amelioration of EAE by agg Ig-PLP1. (a) Groups of mice (eight per group) were induced for EAE with 100 μg PLP1 and then treated with 300 μg of agg Ig-PLP1 or agg Ig-W in PBS on days 9, 13, and 17 after disease induction. (b) Direct comparison of the disease course of PLP1 peptide induced EAE after treatment with sol Ig-PLP1 (from Fig. 1) versus agg Ig-PLP1 (from 2 a). Each point represents the mean clinical score of eight mice. These results are representative of three independent experiments. The 900 μg agg Ig-PLP1 given to mice contains ∼12 nmol PLP1. This amount is ∼17-fold lower than the 200 nmol given as free PLP1, yet disease modulation was much more effective.